This trial is active but is no longer accepting patients.
This is a Phase Ib/II, open-label, multi-center, competitive enrollment and dose escalation
study of ALT-803 in patients with relapsed or refractory multiple myeloma.
What is the phase of this trial?
Phase 1/2 what does this mean
What type of trial is this?
This is an interventional trial. This type of trial actively treats your myeloma.
What treatments are used in this trial?
How many patients will participate in this trial?
Approximately 50 patients will be enrolled in this study.
Who is sponsoring this trial?
Altor Bioscience Corporation
SparkCures Trial Identifiers
, NCT02099539 what is this